Literature DB >> 2450281

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

M E Patarroyo1, R Amador, P Clavijo, A Moreno, F Guzman, P Romero, R Tascon, A Franco, L A Murillo, G Ponton.   

Abstract

We have previously shown that a mixture of three synthetic peptides (83.1, 55.1, 35.1), corresponding to fragments of the relative molecular mass 83,000 (83K), 55K and 35K Plasmodium falciparum merozoite-specific proteins, induces protection in Aotus triviroatus monkeys experimentally infected with P. falciparum. Here we describe two polymeric synthetic hybrid proteins based on these peptides that delay or suppress the development of parasitaemia in immunized human volunteers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450281     DOI: 10.1038/332158a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  66 in total

1.  Inhibition of bacterial superantigens by peptides and antibodies.

Authors:  K Visvanathan; A Charles; J Bannan; P Pugach; K Kashfi; J B Zabriskie
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro.

Authors:  R Moreno; F Pöltl-Frank; D Stüber; H Matile; M Mutz; N A Weiss; G Pluschke
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  Afebrile Plasmodium falciparum parasitemia decreases absorption of fortification iron but does not affect systemic iron utilization: a double stable-isotope study in young Beninese women.

Authors:  Colin I Cercamondi; Ines M Egli; Ella Ahouandjinou; Romain Dossa; Christophe Zeder; Lamidhi Salami; Harold Tjalsma; Erwin Wiegerinck; Toshihiko Tanno; Richard F Hurrell; Joseph Hounhouigan; Michael B Zimmermann
Journal:  Am J Clin Nutr       Date:  2010-10-06       Impact factor: 7.045

Review 4.  Vaccines for preventing malaria (SPf66).

Authors:  P Graves; H Gelband
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 5.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

6.  Isolation and serological characterization of a Plasmodium vivax recombinant antigen.

Authors:  Y D Sharma; V P Sharma; P Ray; S Laal; S D Sawant; S Verma
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

Review 7.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

8.  Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.

Authors:  Y P Shi; S E Hasnain; J B Sacci; B P Holloway; H Fujioka; N Kumar; R Wohlhueter; S L Hoffman; W E Collins; A A Lal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Identification of an erythrocyte binding peptide from the erythrocyte binding antigen, EBA-175, which blocks parasite multiplication and induces peptide-blocking antibodies.

Authors:  P H Jakobsen; P M Heegaard; C Koch; K Wasniowska; M M Lemnge; J B Jensen; B K Sim
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

10.  Onchocerca volvulus larval antigen, OvB20, induces partial protection in a rodent model of onchocerciasis.

Authors:  M J Taylor; N Abdel-Wahab; Y Wu; R E Jenkins; A E Bianco
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.